Casa
asdas

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Por um escritor misterioso

Descrição
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Treating to Target(s) With Interleukin-17 Inhibitors - Charles W. Lynde, Jennifer Beecker, Jan Dutz, Cathy Flanagan, Lyn C. Guenther, Wayne Gulliver, Kim Papp, Proton Rahman, Dalton Sholter, Gordon E. Searles, 2019
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Changes from baseline in ASDAS and BASFI over time. Dashed line: all
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Baseline characteristics of patients included in the two treatment arms
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
PDF] ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. - Abstract - Europe PMC
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Management of axial spondyloarthritis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
SIMPONI ARIA® Ankylosing Spondylitis: ASAS Response Rates
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
ARA Abstracts - 2020 - Internal Medicine Journal - Wiley Online Library
de por adulto (o preço varia de acordo com o tamanho do grupo)